Introduction: Hydroxyurea (HU) is a drug that targets the underlying pathophysiology of sickle cell disease (SCD); however, it continues to be an underutilized treatment for adults. Previous research suggests that HU treatment can result in fewer hospital contacts for acute vaso-occlusive pain crises (VOC). Hydroxyurea's impact on non-VOC pain, however, is not well established.
Introduction
Sickle cell disease (SCD) is a collection of congenital hemoglobinopathies that causes erythrocyte malformations. These "sickled" cells promote hemolysis, vaso-occlusion, and tissue hypoxia, 11 leading to a myriad of health complications. Episodes of severe, acute pain, classically attributed to vaso-occlusive crises (VOC), are a hallmark of the disease. Up to 65% of adult patients also experience chronic pain. 30 Whereas VOC pain is acute, episodic, and associated with ischemic events, the etiology of noncrisis chronic pain (ie, non-VOC pain) is complex and poorly understood. 16 Central sensitization (CS), or plasticity of neurons in response to inflammation or injury, 34 is one possible cause of non-VOC pain. 3, 13 Contemporary theory suggests peripheral neuron hyperexcitability-likely triggered by VOCs, organ complications, and opioid use-might have compounding effects on central pain modulation systems, 32 contributing to the amplification and facilitation of nociception. 22 In patients with SCD, previous work suggests that CS is associated with lower fetal hemoglobin levels, 17 which is a modulator of SCD severity. 4 Treatments targeting fetal hemoglobin might reduce CS and non-VOC pain 17 ; however, no study has previously examined such effects.
Hydroxyurea (HU), an FDA-approved treatment, decreases the proportion of sickled cells by increasing fetal hemoglobin, 10 which reduces hemoglobin polymerization and inhibits noxious Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
enzymes. 2 Positive outcomes associated with HU include reductions in early mortality, 29 acute VOCs, 15 and daily symptom interference. 31 Because few studies have examined HU's impact on non-VOC pain, 9 this study tested the hypotheses that (1) non-VOC pain would be less severe in SCD adults taking HU (HU1) compared with those not taking HU (HU2), and (2) CS, captured by quantitative sensory testing (QST), 5 would be reduced among HU1 individuals.
Methods
This secondary analysis uses data from a case-control protocol examining pain processing and daily function in SCD adults. [12] [13] [14] 24 Previously reported sample sizes vary based on data collection stage and aim. This study uniquely focuses on HU's association with evoked and clinical pain to address the knowledge gap about HU and non-VOC pain. 9 Hydroxyurea is indicated for individuals with hemoglobin (Hb) SS and Hb Beta 0 thalassemia, so this study only includes data from participants with these genotypes (n 5 58). The Institutional Review Board for Johns Hopkins University approved all study-related procedures, and all participants provided written consent.
Data collection procedures
Inclusion and exclusion criteria are listed in our previous work.
12 -14,24 Phone-screened eligible individuals attended an inperson visit on a day of typical pain (but ,5/10 intensity) with no VOCs in the previous 3 weeks. Consented participants completed questionnaires, QST, and daily electronic diaries for 12 weeks.
Measures

Quantitative sensory testing
Detailed QST procedures were previously described (see Refs. 12 and 13). Briefly, we assessed pain threshold and tolerance (ie, static QST measures) as well as temporal summation of pain (ie, dynamic QST measures). Heat pain threshold and tolerance stimuli were delivered using a Peltier element-based stimulator (Medoc, Israel; Pathway, Advanced Thermal Stimulator thermode) applied on the ventral forearm with an ascending method of limits paradigm that had a 0.5˚/sec rise rate. Mechanical pain threshold stimuli were delivered twice each using an algometer (SBMedic) with a 1-cm 2 hard rubber probe applied bilaterally on the trapezius muscle, interphalangeal joint of the thumb, the proximal third of the forearm, and the middle of the quadriceps insertion point.
Thermal temporal summation was assessed through the PATHWAY CHEPS (Contact Heat-Evoked Potential Stimulator) thermode using 10 heat pulses spaced by 2.5 seconds with a rise rate of 70˚/sec. Mechanical temporal summation was assessed through hand-crafted punctate probes according to the German Research Network protocol. Participants indicated peak pain over 10 stimuli with varying forces between 128 mN and 256 mN delivered 1 second apart.
Daily electronic symptom monitoring
Participants completed daily diaries for 12 weeks after the visit, providing daily average pain intensity ratings on a 0 to 100 scale. Pain ratings were categorized as "VOC" or "non-VOC" based on separately averaged ratings for crisis and noncrisis days, respectively. Data from individuals with $25% completed days were included.
Data analyses
The sample was dichotomized based on reported HU use. Skewed and kurtotic variables were log-transformed. Quantitative sensory testing measures and clinical pain were compared using analysis of covariance to control for opioid use. Because this study represents a preliminary analysis of a novel topic, we did not correct for multiple comparisons to minimize the likelihood of type II error 6, 18, 27 ; results should be interpreted cautiously.
Results
Participants
Of the 58 participants, 17 endorsed regular HU use (SS genotype 5 16). Table 1 reports demographic characteristics. All individuals were African American/black, and one individual identified as Hispanic (HU2 group). Chi-squared tests showed no group differences in sex (P 5 0.984), ethnicity (P 5 0.519), and education (P 5 0.241). There were no differences in age (P 5 0.14) or daily morphine equivalents (P 5 0.431). HU1 participants had significantly lower white blood cell counts than HU2 participants (t 56 5 23.1, P 5 0.004), demonstrating HU's therapeutic efficacy. Figure 1 shows results from analyses of covariance comparing groups on measures of static (Fig. 1A, B) and dynamic (Fig. 1C) pain processing. Total daily morphine equivalents were positively associated with mechanical pain threshold in the thumb (P 5 0.03), quadriceps (P 5 0.02), and forearm (P 5 0.08, trend) but not heat pain threshold/tolerance (P 5 0.98, 0.63, respectively), trapezius pain threshold (P 5 0.23), or temporal summation (Ps . 0.12). On static QST measures, HU1 individuals demonstrated significantly higher thermal pain threshold (F 1,52 5 9.2, P 5 0.004, h 
Quantitative sensory testing
Clinical pain ratings
Forty-seven percent of HU1 and 63% of HU2 participants reported non-VOC pain (Fisher's Z 5 1. Table 2 provides QST and clinical pain descriptive statistics, and Figure 2 depicts differences in diary pain ratings averaged over a 12-week period.
Discussion
Findings from this study did not support our hypotheses. HU1 participants did not report significantly lower non-VOC pain on daily diaries, nor did they show evidence of reduced pain facilitation on dynamic QST measures. Instead, HU1 participants reported significantly lower VOC pain and had lower pain thresholds on static QST measures (ie, thermal pain and mechanical pain across the 4 testing sites) compared with HU2 individuals. This effect remained after controlling for total daily morphine equivalents, suggesting that opioid use did not confound the present results.
Previous work supports our finding of reduced VOC pain ratings in SCD individuals treated with HU. 2, 7, 10, 15, 21, 33 Hydroxyurea's ability to increase levels of fetal hemoglobin, 15, 19 change erythrocyte properties, 8, 26 and decrease cell adhesion 1 results in reduction of inflammatory mediators in the periphery. 23 It is possible, then, that our finding of lower static QST ratings among HU1 participants reflects treatment-induced changes in peripheral pain mechanisms.
Alternatively, we did not observe differences in non-VOC pain ratings, nor dynamic QST measures. Non-VOC pain in SCD has been described as a potential interaction of peripheral and CS mechanisms. 20 Furthermore, the selected dynamic QST measures are used to probe sensitization of the central nervous system. 28 Combined, these findings suggest that CS is not directly influenced through HU treatment. Future, large-scale studies yielding normative QST values for individuals with SCD will help track changes in pain processing over the course of HU treatment.
Limitations
Our study had limitations for future work to expand upon. First, this study is a small, secondary analysis with cross- sectional reporting of HU use. Sickle cell disease is a rare disorder in the United States, which limits sample sizes. Second, we did not collect information about HU treatment duration or dosing over time. It is possible that long-term or early-initiated treatment impacts CS progression. Given the study's cross-sectional nature, we cannot speak to whether early HU initiation might prevent the development of non-VOC pain. Third, we did not collect information about adherence to HU, which might confound outcomes. 7 Finally, future research is encouraged to examine a larger cohort of individuals taking HU to address this study's limitation of unequal sample sizes. Although these limitations support cautious interpretation of these results, findings suggest that HU more robustly impacts VOC than non-VOC pain mechanisms.
Conclusion
Non-VOC pain remains understudied 30 and, critically, powerfully impacts quality of life in individuals with SCD. 25 The present results suggest that HU is not associated with lower non-VOC pain but is robustly related to better VOC outcomes. Future research is encouraged to establish alternative treatments acting on central pain mechanisms in SCD to address non-VOC pain.
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